Zevra Therapeutics Inc expected to post earnings of 11 cents a share - Earnings Preview

Zevra Therapeutics

03/08/2026 22:27

Zevra Therapeutics Inc ZVRA.OQ ZVRA.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Celebration Florida-based  company is expected to report a 30.9% increase in revenue to $33.881 million from $25.88 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Zevra Therapeutics Inc is for earnings of 11 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Zevra Therapeutics Inc is $24.50, about 157.6% above its last closing price of $9.51
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
0.09
0.08
0.18
Beat
122.8
Dec. 31 2026
0.07
0.05
0.21
Beat
320
Sep. 30 2025
-0.04
-0.03
-0.01
Beat
71.4​
Jun. 30 2025
1.54
1.50
1.21
Missed
-19.2
​​Mar. 31 2025
-0.19
-0.19
-0.06
Beat
67.9
Dec. 31 2024
-0.40
-0.40
-0.69
Missed
-70.7​
Sep. 30 2024
-0.42
-0.42
-0.69
Missed
-63.8
Jun. 30 2024
-0.44
-0.43
-0.48
Missed
-10.6
This summary was machine generated August 3 at 21:27 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)